Diagnosing Brain Conditions by Watching Lab-Grown Neurons Light Up
This patent describes a method to diagnose brain disorders by taking a patient's cell, turning it into a neuron, making it glow when active, and comparing its light patterns to a genetically matched healthy cell.
Original patent title: “Diagnostic methods for neural disorders”
This patent describes a method to diagnose brain disorders by taking a patient's cell, turning it into a neuron, making it glow when active, and comparing its light patterns to a genetically matched healthy cell. Granted in 2026.
Coverage
What does this patent actually cover?
The patent describes a method to diagnose neuronal conditions. It involves taking a patient's cell and converting it into a neuron. This engineered neuron is then modified to include an "optical reporter," which means it will show a light-based "optical signature" when stimulated, reflecting its electrical activity or "action potentials." To understand the effect of a specific genetic change, a control neuron is created using "genome-editing." This control neuron is genetically identical ("isogenic") to the patient's neuron, except for the single mutation being studied. By comparing the optical signature of the patient's neuron to this control, any differences can be linked to the mutation and used to diagnose a "neurodegenerative disease," such as Alzheimer's or Parkinson's. For example, a patient with suspected Parkinson's disease could have their skin cells converted into neurons, made to glow, and their activity patterns compared to an edited, healthy version of their own neuron to identify disease-related changes.
The gap
What does this patent NOT cover?
- Does not cover diagnostic methods that rely solely on electrical measurements of neurons without an optical reporter.
- Does not cover diagnosing neuronal conditions directly within a living patient's body, as it specifies "in vitro" evaluation.
- Does not cover methods that use non-neuronal cells or existing neurons from a patient without converting them.
- Does not cover diagnostic approaches that do not involve creating and comparing to an isogenic control cell.
- Does not cover methods that detect neuronal activity using chemical or mechanical means rather than optical signals.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in creating patient-specific neurons, making them optically active, and then using genome editing to create an *isogenic* control. This allows for a highly precise comparison to see the effect of a single genetic mutation within that patient's unique genetic background.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Research labs studying neurodegenerative diseases like Alzheimer's or ALS
Drug discovery platforms for neurological disorders
Personalized medicine approaches for brain conditions
Why it matters
The bigger picture
This method offers a precise way to study neurodegenerative diseases in a patient-specific manner, outside the human body. It helps researchers understand how specific genetic mutations contribute to these complex conditions. This approach could lead to more personalized diagnoses and allow for testing potential drug treatments on a patient's own cells before administering them.
Filed
February 24, 2020
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Companies and academic institutions focused on induced pluripotent stem cell (iPSC) technology and genome editing are active in this space. Firms like Fujifilm Cellular Dynamics International (CDI) and Stemcell Technologies develop iPSC-derived cells for research. Biotech startups specializing in personalized medicine and neurodegenerative disease modeling are also exploring similar diagnostic and drug screening approaches.
Market impact
As this patent was granted recently in 2026, its full market impact is yet to unfold. However, it aims to enable a new generation of patient-specific diagnostics for neurodegenerative diseases. This could lead to more accurate early detection and personalized treatment strategies, potentially influencing how pharmaceutical companies screen and develop drugs for complex brain disorders by providing better in vitro models.
Claim 1 — Plain English
What this patent covers
The patent describes a method to diagnose neuronal conditions. It involves taking a patient's cell and converting it into a neuron. This engineered neuron is then modified to include an "optical reporter," which means it will show a light-based "optical signature" when stimulated, reflecting its electrical activity or "action potentials." To understand the effect of a specific genetic change, a control neuron is created using "genome-editing." This control neuron is genetically identical ("isogenic") to the patient's neuron, except for the single mutation being studied. By comparing the optical signature of the patient's neuron to this control, any differences can be linked to the mutation and used to diagnose a "neurodegenerative disease," such as Alzheimer's or Parkinson's. For example, a patient with suspected Parkinson's disease could have their skin cells converted into neurons, made to glow, and their activity patterns compared to an edited, healthy version of their own neuron to identify disease-related changes.
The clever bit
The novelty lies in creating patient-specific neurons, making them optically active, and then using genome editing to create an *isogenic* control. This allows for a highly precise comparison to see the effect of a single genetic mutation within that patient's unique genetic background.
What it does not cover
- Does not cover diagnostic methods that rely solely on electrical measurements of neurons without an optical reporter.
- Does not cover diagnosing neuronal conditions directly within a living patient's body, as it specifies "in vitro" evaluation.
- Does not cover methods that use non-neuronal cells or existing neurons from a patient without converting them.
- Does not cover diagnostic approaches that do not involve creating and comparing to an isogenic control cell.
- Does not cover methods that detect neuronal activity using chemical or mechanical means rather than optical signals.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$18K – $58K
Midpoint $36K · 13.4 yr remaining · industry ×1.5
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Diagnosing Brain Conditions by Watching Lab-Grown Neurons Light Up (U.S. Patent No. 12,736,528). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12736528/diagnostic-methods-for-neural-disorders
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12736528"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 20220283184
Diagnosing Brain Diseases by Measuring a Protein in Blood or Urine
US 20200371093 · Medicortex Finland Oy
Checking if Brain Injury Drugs Work Using Saliva or Urine
US 12376789 · 2025 · Chosun University Industry Academic Cooperation Foundation
How Computers Use Brain Maps to Diagnose Alzheimer's Disease
US 12735703 · 2026
How Oligonucleotides Target C9orf72 for Brain Diseases
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Diagnosing Brain Conditions by Watching Lab-Grown Neurons Light Up cover?
This patent describes a method to diagnose brain disorders by taking a patient's cell, turning it into a neuron, making it glow when active, and comparing its light patterns to a genetically matched healthy cell.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
This method offers a precise way to study neurodegenerative diseases in a patient-specific manner, outside the human body. It helps researchers understand how specific genetic mutations contribute to these complex conditions. This approach could lead to more personalized diagnoses and allow for testing potential drug treatments on a patient's own cells before administering them.
What does this patent NOT cover?
Does not cover diagnostic methods that rely solely on electrical measurements of neurons without an optical reporter.
Patent monitoring